These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3615798)

  • 1. Dengue virus vaccine studies in Puerto Rico: a review.
    Kraiselburd E
    P R Health Sci J; 1987 Apr; 6(1):27-9. PubMed ID: 3615798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
    Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
    Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurovirulence effects of dengue-2 viruses on the rhesus (Macaca mulatta) brain and spinal cord.
    Angsubhakorn S; Moe JB; Marchette NJ; Palumbo NE; Yoksan S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 1987 Mar; 18(1):52-5. PubMed ID: 3660068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
    Angsubhakorn S; Yoksan S; Pradermwong A; Nitatpattana N; Sahaphong S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 1994 Sep; 25(3):554-9. PubMed ID: 7777925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
    Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
    BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
    Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
    Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of dengue vaccines and prospects for the future.
    Bancroft WH
    P R Health Sci J; 1987 Apr; 6(1):23-6. PubMed ID: 3615797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
    Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research on dengue in tissue culture. V. Production of anti-dengue antibodies in tissue cultures from monkeys inoculated with an attenuated type I dengue virus strain.
    Fujita N; Izaki S; Oda K; Kimura E; Hotta S
    Kobe J Med Sci; 1972 Sep; 18(3):143-52. PubMed ID: 4200059
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.
    Raviprakash K; Apt D; Brinkman A; Skinner C; Yang S; Dawes G; Ewing D; Wu SJ; Bass S; Punnonen J; Porter K
    Virology; 2006 Sep; 353(1):166-73. PubMed ID: 16814355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris.
    Guzmán MG; Rodríguez R; Rodríguez R; Hermida L; Alvarez M; Lazo L; Muné M; Rosario D; Valdés K; Vázquez S; Martinez R; Serrano T; Paez J; Espinosa R; Pumariega T; Guillén G
    Am J Trop Med Hyg; 2003 Aug; 69(2):129-34. PubMed ID: 13677367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
    Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
    Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.
    Blair PJ; Kochel TJ; Raviprakash K; Guevara C; Salazar M; Wu SJ; Olson JG; Porter KR
    Vaccine; 2006 Feb; 24(9):1427-32. PubMed ID: 16214271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
    Raviprakash K; Marques E; Ewing D; Lu Y; Phillips I; Porter KR; Kochel TJ; August TJ; Hayes CG; Murphy GS
    Virology; 2001 Nov; 290(1):74-82. PubMed ID: 11883007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.